Articles tagged with Heparin
A team of Virginia Tech researchers has discovered new insights into blood thinners and bone builders, heparin. The findings may lead to designing safer and more reliable heparin therapies. Heparin's molecular composition affects its ability to bind calcium, influencing its effectiveness in biomineralization and blood clotting.
A rare but deadly reaction to the blood thinner heparin is caused by a single antibody, according to a new study published in the New England Journal of Medicine. The discovery could lead to more precise diagnostics and targeted treatments for patients.
Researchers investigated the effectiveness of systemic thrombolysis for acute portal vein thrombosis (PVT) in liver cirrhosis patients. After a 7-day treatment period, 60% of patients achieved full recanalization of the portal vein, with no significant side effects.
A new anticoagulant with on-demand reversible activity has been developed by a team from UNIGE and the University of Sydney. This breakthrough offers a more reliable and easier-to-use option for surgical procedures, reducing the risk of serious bleeding associated with current treatments.
Researchers at Rensselaer Polytechnic Institute have developed a patented process to produce heparin in the lab, offering a consistent and safe supply of the essential medicine. The discovery has the potential to revolutionize the production of heparin, reducing reliance on animal-derived sources and addressing global supply chain issues.
Researchers at Fralin Biomedical Research Institute and Carilion Clinic found that preserving leg vein grafts in heparinized arterial blood, rather than saline, improves their health and viability. This discovery could lead to better outcomes for patients undergoing coronary artery bypass graft procedures.
Researchers have discovered a link between adenovirus infection and an anti-platelet factor 4 disorder, which can cause severe thrombocytopenia. The condition is rare and potentially fatal, and has been reported in patients with viral symptoms and no exposure to heparin or vaccines.
ClearTau overcomes limitations of previous methods by producing Tau fibrils efficiently and consistently. This allows researchers to study the development of tauopathies and develop disease-specific therapeutics.
The American College of Chest Physicians (CHEST) has released a new clinical guideline for managing antithrombotic therapy in patients with COVID-19-related arterial thrombosis and thromboembolism. The guideline provides evidence-based recommendations to improve risk-evaluation and treatment course.
The study reveals that the midgut gland of Japanese scallops is a valuable source of fucosylated heparan sulfate, exhibiting anticoagulating and neurite outgrowth-promoting activities. Fuc-HS shows resistance to GAG-degrading enzymes, indicating its unique structure with a fucosyl group attached to GlcA.
A new clinical trial of over 12,000 patients found that inexpensive aspirin is just as effective as injectable blood thinners in preventing life-threatening blood clots and other complications. The study suggests that surgeons may change their practice to administer aspirin to patients hospitalized with bone fractures.
A cost-effectiveness analysis of direct oral anticoagulants (DOACs) versus low-molecular-weight heparin (LMWH) for cancer-associated thrombosis found that DOACs are more medically effective and cost-effective. The most cost-effective DOAC, apixaban, was also shown to be the least costly anticoagulant.
A new study has shown that bivalirudin is a safer and more effective anticoagulant than heparin for treating heart attack patients. The trial found that bivalirudin significantly reduced death, major bleeding, and thrombosis in patients undergoing percutaneous coronary intervention.
A new daily anti-clotting pill, edoxaban, shows promise in preventing bleeding and clotting instances rare in children with heart conditions. The study's findings indicate edoxaban is a viable alternative to current treatments, eliminating injections and reducing frequent blood tests.
The new guideline provides evidence-based recommendations for managing patients on warfarin, DOACs, and antiplatelet drugs before and after surgeries. It aims to minimize preventable bleeding and thrombotic events by standardizing approaches and protocols.
Hospitalized COVID-19 patients with high blood viscosity have a 60% higher death rate than those with low blood viscosity. The study suggests that checking for blood viscosity early on could help determine the best treatment course and improve outcomes.
Researchers at the University of Copenhagen have made a groundbreaking discovery that could phase out medications derived from pig intestines. The team has successfully created a synthetic alternative to heparin in a laboratory setting, using cell factories, similar to insulin production.
Researchers found that inhaling heparin improves breathing and oxygen levels in 70% of COVID-19 patients, with the drug also showing anti-viral, anti-inflammatory, and anti-coagulant effects. This low-cost treatment could provide a safe and effective option for patients in poorer countries where vaccination is challenging.
A study published in Cardiovascular Research found that an anticoagulant medication can improve the survival of COVID-19 patients and shorten the duration of active SARS-CoV-2 infection. The medication, low-molecular-weight heparin, also curtails viral persistence by inhibiting the virus's ability to bind to cells.
A clinical trial of 465 patients found that administering heparin in therapeutic doses reduced mortality from COVID-19 by 78%, with benefits only observed when administered between seven and 14 days after symptom onset. The study suggests that timing is crucial for treatment efficacy.
The RAPID Trial found that administering a full dose of heparin early to moderately ill hospitalized patients with COVID-19 could reduce the risk of severe disease and death. The study showed a significant reduction in all-cause death with therapeutic heparin compared to low-dose treatment.
A new analytical approach for detecting contaminants in Heparin has been developed, increasing sensitivity by over 100 times and reducing analysis time and material requirements. This technique has the potential to improve the quality and safety of the widely used anticoagulant drug.
A new case report details the treatment of a patient with VITT (vaccine-induced thrombotic thrombocytopenia) using bivalirudin, an alternative to heparin. Early outcomes suggest that this approach may be safe and effective in treating these rare but serious clot reactions.
Research finds heparin inhibits SARS-CoV2 virus spike protein, reducing its ability to attach and infect human cells. The study suggests inhaled unfractionated heparin could be a rapid treatment option for Covid-19 patients.
A meta-analysis of bivalirudin versus heparin in patients with myocardial infarction (MI) found that bivalirudin was associated with similar overall rates of 30-day mortality but lower rates of serious bleeding. In STEMI patients, bivalirudin use reduced all-cause mortality and serious bleeding.
Researchers found seaweed extracts to be more effective than remdesivir in blocking SARS-CoV-2 infection in mammalian cells. The decoy strategy involves locking onto a similar molecule on the surface of human cells, trapping and degrading the virus.
Researchers at Rensselaer Polytechnic Institute found that heparin, a common blood thinner, can effectively neutralize the SARS-CoV-2 virus. The drug binds tightly to the surface spike protein of the virus, preventing it from infecting human cells and potentially reducing the severity of COVID-19 symptoms.
Researchers developed a new method to apply anti-inflammatory substances to implants to reduce undesirable inflammatory reactions. The coatings contain heparin and hyaluronic acid, which inhibit the immune system's response to the implant.
Brazilian pulmonologist Dr. Elnara Negri argues that COVID-19 should be treated as a thrombotic disease, citing the use of anti-coagulant drug heparin to improve patient outcomes. She reports a successful treatment protocol with 80 patients, with none dying and four in ICU.
A new study suggests that butterfly and moth eyespots likely evolved independently, with distinct developmental pathways.
Researchers at UC San Diego discovered the critical gene ZNF263, which regulates heparin biosynthesis in human cells. This breakthrough could enable the production of heparin in well-controlled cell culture, providing a safer and more sustainable alternative to current methods.
A new method called Shotgun ion mobility mass spectrometry sequencing (SIMMS2) has been invented to map the structures of heparan sulfates, which play key roles in regulating biological functions. This breakthrough could lead to the development of new therapeutics for diseases such as cancer and neurodegenerative disorders.
Researchers have developed a new approach to improving spinal fusion procedures and repairing broken bones. By delivering a potent bone-forming protein called BMP using a heparin mixture, they significantly reduced undesired bone growth outside of targeted repair areas in rat femurs.
Researchers at LMU have discovered that inhibition of a specific enzyme can effectively prevent heparin-induced thrombocytopenia (HIT), a potentially life-threatening condition. The study shows that Btk inhibitors can block platelet activation and prevent the formation of harmful clots, offering a new promising therapeutic option for t...
Researchers discuss bivalirudin's role in reducing bleeding complications and its potential for increased acute stent thrombosis risk. The study aims to clarify the optimal anticoagulation strategy for interventional cardiovascular procedures.
A simpler and quicker method for detecting the impurity in heparin has been developed by Jason Dwyer, associate professor of chemistry at the University of Rhode Island. The technique uses a sensing method proven in DNA sequencing and can fingerprint heparin to detect contaminants.
Researchers found that patients with acute kidney injury had higher VTE rates despite prophylaxis, highlighting the need for optimal heparin dosing in these cases. The study also showed that creatinine clearance was not associated with VTE rates when unfractionated or low-molecular-weight heparins were given.
A chemically modified version of heparin shows promise in reducing brain swelling and inflammation after traumatic brain injury in mice. The new treatment, ODSH, is being tested in a Phase II clinical trial to assess its effectiveness in people with TBI.
A synthetic version of low molecular weight heparin, proven safe and effective in preclinical trials, is set to enter clinical trials. The new compound offers several advantages over its natural counterpart, including reduced risk of contamination and improved safety for patients with poor kidney function.
Researchers found that heparin stimulates AgRP neurons in the hypothalamus, increasing production of a neuropeptide that stimulates food intake and contributing to increased body weight. The study suggests heparin may be a potential target for treating eating disorders and obesity.
The EMANATE trial shows that apixaban lowers stroke risk in anticoagulation-naïve patients with atrial fibrillation scheduled for elective cardioversion. Patients treated with apixaban had fewer strokes than those receiving usual care, with similar bleeding rates to warfarin.
A meta-analysis of randomized-clinical trials found that full-dose bivalirudin infusion post-PCI for four hours is associated with improved net adverse clinical events and all-cause mortality. Bivalirudin exhibits a lower risk of bleeding compared to unfractionated heparin, but also increases the risk of acute stent thrombosis.
A subgroup analysis of the BRAVO-3 trial found that patients with balloon expandable valves had a different baseline profile than those treated with non-balloon expandable valves. This suggests that differences in patient characteristics, not valve type, drive TAVR outcomes.
Researchers at North Carolina State University have developed a smart patch that monitors a patient's blood and releases blood-thinning drugs as needed. The patch, made with microneedles containing hyaluronic acid and Heparin, can prevent thrombosis in animal models, offering a more effective treatment than traditional methods.
A new study by Intermountain Medical Center Heart Institute found that two different blood clot prevention medications are just as safe and effective for patients undergoing percutaneous coronary intervention. The risk of major bleeding after 30 days was low and not significantly different between the two treatment methods.
The US Food and Drug Administration is making surprise visits to heparin plants in China to verify animal origins. Researchers are also working on developing a synthetic version of the drug to diversify sources.
A new study by Loyola University Chicago Stritch School of Medicine researchers has found that bovine heparin has equivalent anti-clotting properties to porcine heparin. This breakthrough could help address possible shortages of the essential medication, which is primarily derived from pigs.
Researchers developed a new therapy by pairing snake venom with nanofibers to promote localized blood clotting at wound sites. The therapy, tested on rats treated with heparin, shows promise for making surgery safer for human patients on blood thinners.
Rice University scientists have developed a nanofiber hydrogel infused with snake venom that can stop bleeding within seconds, even in the presence of anti-coagulants. The material, called SB50, has great potential to treat surgical bleeding in patients taking heparin or other anti-coagulant drugs.
A team of researchers from the University of Pennsylvania School of Medicine has elucidated the structure of a protein complex at its root, which may hold therapeutic potential for treating heparin-induced thrombocytopenia (HIT). The study found that an antibody called RTO disrupts this complex, preventing platelet activation and clot ...
Dr. Peter Berger suggests that the expensive drug offers no clear safety benefits over heparin, which is widely used and effective in lower doses. The MATRIX Trial found no advantages of bivalirudin over heparin in preventing bleeding complications during cardiac stent placement.
A statewide quality improvement program helped reduce serious blood clot complications by more than half in Michigan trauma centers. The program, which provides data-driven feedback and best practices, led to a significant drop in venous thromboembolism events after switching from one anti-clotting agent to another.
A large registry study found that patients experiencing stent thrombosis between 2-30 days post-procedure had higher mortality rates compared to those who developed the complication within 24 hours. The timing of stent thrombosis may be linked to more severe infarction and long-term heart failure.
A Northwestern University team has re-engineered a common drug to deliver nitric oxide, preventing cellular overgrowth and scarring in blood vessels during and after surgery. This modified protamine sulfate can slowly release nitric oxide, minimizing its negative effects while maintaining its function as an antidote for heparin.
The BRIGHT trial demonstrated the superiority of bivalirudin over heparin monotherapy and heparin plus tirofiban in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Bivalirudin reduced bleeding rates while maintaining comparable rates of major adverse cardiac events.
Researchers found that therapeutic plasma exchange can rapidly reduce HIT antibody levels, making patients eligible for urgent cardiac surgery sooner. The study suggests using both functional and immunoassays to determine patient readiness, with the functional assay indicating lower antibody levels more quickly.
A team of UBC researchers has developed a synthetic antidote that can reverse the effects of all types of heparin used in clinics. The breakthrough has significant implications for cardiothoracic surgery and anticoagulant-related bleeding problems.
A study analyzed all trials to date, finding that bivalirudin-based regimens increase the risk of heart attacks and stent thrombosis, while heparin-based regimens decrease bleeding risk. The magnitude of benefit was attenuated when glycoprotein IIb/IIIa inhibitor use was similar in both arms.
A new study published in The Lancet compares two drugs used to prevent blood clot formation during emergency heart attack treatment. The results suggest that systematic use of heparin rather than bivalirudin after primary percutaneous coronary intervention (PPCI) could save health services substantial sums of money while potentially im...
Researchers at Duke University Medical Center have identified a new strategy for treating neuroblastoma using a modified version of heparin. The study found that the derivative suppressed and shrunk neuroblastoma tumors in mice without causing severe bleeding.